HOPE Therapeutics Secures $7.8M to Expand Mental Health Clinic Network
May 15th, 2025 4:35 PM
By: Advos Staff Reporter
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has obtained $7.8 million in acquisition funding to launch a national interventional psychiatry clinic network focused on treating severe depression and PTSD, with initial clinic acquisitions already planned.
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has secured $7.8 million in acquisition funding from Universal Capital, LLC, to expand its national interventional psychiatry clinic network. The investment brings HOPE's total available capital to $10.3 million, enabling strategic acquisitions of mental health clinics specialized in neuroplastic treatments.
The funding will support immediate acquisitions of Dura Medical, Kadima, and NeuroSpa clinics, which offer advanced treatments like ketamine and transcranial magnetic stimulation for severe depression and post-traumatic stress disorder (PTSD). These clinics currently have contracts to serve veterans through the Department of Veterans Affairs, indicating an established patient base and potential for growth.
The clinic network expansion represents a significant development in mental health treatment accessibility, particularly for populations with treatment-resistant conditions. By consolidating specialized clinics, HOPE Therapeutics aims to create a comprehensive platform for innovative psychiatric care across the United States.
Universal Capital has indicated potential participation in future funding rounds, suggesting long-term confidence in HOPE Therapeutics' strategic vision and the growing market for advanced mental health interventions.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
